Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Task-Oriented Training for Rehabilitation in Multiple Sclerosis in a Non-Hospital Setting: A Protocol for a Randomized Controlled Trial.
Toxocara seropositivity in sensory-predominant cervical myelitis from an endemic region: A six-case series and systematic review.
Aquaporin-4 Antibody-Positive Optic Neuritis: A Comparison of Clinical Characteristics and Visual Prognosis Between Two Consecutive Decades.
A Qualitative Study of Lived Treatment Experiences and Preferences of Long-Term DMT Users with Relapsing-Remitting Multiple Sclerosis.
Irisin as a driver of neuroprotection in multiple sclerosis.
Explainable Artificial Intelligence to Predict Neurocognitive Disorder Progression in Multiple Sclerosis Using MRI and Clinical Data.
7T magnetic resonance imaging of the human spinal cord in multiple sclerosis: Advances, insights and unmet needs.
GABAB receptors in glial cells: from physiological regulation to pathological implications.
C3 and C5 complement cascade activation in brain injury and disease: Molecular mechanisms, pathological roles, and therapeutic implications.
Therapeutic Plasma Exchange in Thailand: A 10-Year Retrospective Analysis.
Treatment approaches to patients with multiple sclerosis and coexisting psoriasis - A longitudinal multicenter observational cohort study.
Identification and Targeted Correction of a Pathogenic Deep Intronic Variant.
Immunotherapy-Mediated Modulation of the Gut Microbiota in Multiple Sclerosis: The Effects of High-Efficacy (Cladribine) and Moderate-Efficacy (Interferon Beta-1a) Treatments.
Web of Science Bibliometrics Analysis of Magnetic Resonance Imaging Research Advances in Multiple Sclerosis.
Recalibration and external validation of vascular risk calculators for multiple sclerosis: A population-based study using CPRD data in England, 1987-2023.
[Effects of electroacupuncture on HMGB1/RAGE/NF-κB pathway-mediated inflammatory response and reactive astrocyte in Parkinson's disease mice].
Functional Connectivity Alterations of the Central Autonomic Network in Multiple Sclerosis: Links to Fatigue and Aerobic Training Effects.
TIM-3-dependent lysosome biogenesis is required for myelin debris clearance in macrophages.
Concerns regarding the 2024 revisions of the McDonald criteria for diagnosis of multiple sclerosis.
Psychosis in multiple sclerosis-a narrative review of an underestimated, but clinically significant problem.
A novel multiplexed biomarker panel reveals key molecular pathways in progressive multiple sclerosis.
Updated systematic literature review and network meta-analysis of cladribine tablets versus currently approved disease-modifying treatments for active relapsing-remitting multiple sclerosis.
Toxic metal exposure and biomarkers of neurotoxic effects: A study in metal recycling workers.
Real-World Treatment Adherence and Persistence with C5 Inhibitor Therapy Versus Satralizumab in Patients with Neuromyelitis Optica Spectrum Disorder in Japan.
Bilateral optic neuritis induced by Adalimumab: A follow-up with visual evoked potentials.
Pages
« first
‹ previous
…
819
820
821
822
823
824
825
826
827
…
next ›
last »